Effects of Insulin in Relatives of Patients with Type 1 Diabetes Mellitus
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: It is unknown whether insulin therapy can delay or prevent diabetes in nondiabetic relatives of patients with diabetes. METHODS: In a randomized, controlled, nonblinded clinical trial, we screened 84,228 first-degree and second-degree relatives of patients with diabetes for islet-cell antibodies; 3152 tested positive; 2103 of the 3152 underwent genetic, immunologic, and metabolic staging to quantify their risk; 372 of the 2103 had a projected five-year risk of more than 50 percent; 339 of the 372 (median age, 11.2 years) were randomly assigned to undergo either close observation or an intervention that consisted of low-dose subcutaneous ultralente insulin, administered twice daily for a total dose of 0.25 unit per kilogram of body weight per day, plus annual four-day continuous intravenous infusions of insulin. Oral glucose-tolerance tests were performed every six months. Median follow-up was 3.7 years. The primary end point was a diagnosis of diabetes. RESULTS: Diabetes was diagnosed in 69 subjects in the intervention group and 70 subjects in the observation group. The annualized rate of progression to diabetes was 15.1 percent in the intervention group and 14.6 percent in the observation group. The cumulative incidence of diabetes was similar in the two groups (relative risk in the intervention group as compared with the observation group, 0.96). Most subjects in whom diabetes developed were asymptomatic. Progression to diabetes occurred at a faster rate among subjects with abnormal base-line glucose tolerance (22 percent per year) than among those with normal base-line glucose tolerance (10 percent per year, P<0.001). There were no episodes of severe hypoglycemia. The incidence of chemical hypoglycemia, assessed without ascertainment bias, was similar in the two groups. CONCLUSIONS: In persons at high risk for diabetes, insulin at the dosage used in this study does not delay or prevent type 1 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“but subgroup analyses suggested a benefit of oral insulin in individuals with the highest titres of insulin auto-antibodies.142,143”
From Type 1 diabetes (2018) · cites this paper as [142]
In the citing paper
“The Diabetes Prevention Trial—Type 1, tested whether oral or parental insulin prevented the development of type 1 diabetes in people who were autoantibody positive. Neither approach reduced diabetes development,”
From Type 1 diabetes (2018) · cites this paper as [142]
In the citing paper
“If one islet autoantibody is found, the test should be repeated and the other autoantibodies should be assayed because the risk of type 1 diabetes increases if two or more autoantibodies are positive (443).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [443]
In the citing paper
“Subcutaneously or intranasally delivered insulin was found to have no preventive effects.39,48”
From The future of type 1 diabetes therapy (2025) · cites this paper as [48]
In the citing paper
“Risk can be assessed by islet cell autoantibodies alone, without the need for evaluating endogenous insulin reserves, as was done for the U.S. DPT-1 trial (306).”
From Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus (2011) · cites this paper as [306]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
The Pathogenesis of Insulin-Dependent Diabetes Mellitus
Epstein, F. H., Atkinson, M. A., & Maclaren, N. K. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411243312107 · Cited by 1,078
Verge, C. F., Stenger, D., Bonifacio, E., Colman, P. G., Pilcher, C., Bingley, P. J., & Eisenbarth, G. S. (1998) · Diabetes · doi:10.2337/diabetes.47.12.1857 · Cited by 420
Cognitive Deficits in Adolescents Who Developed Diabetes Early in Life
Ryan, C., Vega, A., & Drash, A. (1985) · Pediatrics · doi:10.1542/peds.75.5.921 · Cited by 413
Insulitis and Diabetes in NOD Mice Reduced by Prophylactic Insulin Therapy
Atkinson, M. A., Maclaren, N. K., & Luchetta, R. (1990) · Diabetes · doi:10.2337/diab.39.8.933 · Cited by 299
Insulin prophylaxis in individuals at high risk of type 1 diabetes
Keller, R. J., Jackson, R. A., Eisenbarth, G. S., & Eisenbarth, G. (1993) · The Lancet · doi:10.1016/0140-6736(93)91215-8 · Cited by 298
Pugliese, A., Gianani, R., Moromisato, R., Awdeh, Z. L., Alper, C. A., Erlich, H. A., Jackson, R. A., & Eisenbarth, G. S. (1995) · Diabetes · doi:10.2337/diab.44.6.608 · Cited by 207
Gotfredsen, C. F., Buschard, K., & Frandsen, E. K. (1985) · Diabetologia · doi:10.1007/bf00703140 · Cited by 205
Vardi, P., Dib, S. A., Tuttleman, M., Connelly, J. E., Grinbergs, M., Radizabeh, A., Riley, W. J., Maclaren, N. K., Eisenbarth, G. S., & Soeldner, J. S. (1987) · Diabetes · doi:10.2337/diab.36.11.1286 · Cited by 192
Attentional Functioning in Children and Adolescents With IDDM
Rovet, J., & Alvarez, M. (1997) · Diabetes Care · doi:10.2337/diacare.20.5.803 · Cited by 153
Cited by
Items 801–832 of 832
HUMORAL IMMUNITY IN TYPE 1 DIABETES MELLITUS
Pietropaolo, M., & Sperling, M. A. (2007) · Elsevier eBooks · doi:10.1016/b978-044452763-9/50053-6
Schiffman, A. B., Murphy, K. M., & Magge, S. N. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-1155-4.00071-7
Sanjeevi, C. B., & Sun, C. (2014) · Springer eBooks · doi:10.1007/978-94-007-6884-0_19-2
Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter
Neu, A., Bürger-Büsing, J., Danne, T., Dost, A., Holder, M., Holl, R. W., Holterhus, P., Kapellen, T. M., Karges, B., Kordonouri, O., et al. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00936-y
Penaforte-Saboia, J. G., Couri, C. E. B., Albuquerque, N. V., Neto, J. S. D. C., Carvalho, G. C., Olegário, N. B. D. C., Linard, L. L. P., Alves, F. G. R., Fernandes, V. O., Montenegro, A. P. D. R., et al. (2022) · doi:10.2196/preprints.40505
Review on Study of A Novel Insulin Delivery Method for the Treatment of Diabetes
Hadge, Y., Gorad, N., Auti, R., Auti, R., & Sivse, S. (2023) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-9558
Advances in Pediatric Pharmacology, Therapeutics, and Toxicology
Paul, I. M., & Berlin, C. M. (2003) · Advances in Pediatrics · doi:10.1016/s0065-3101(23)00059-2
Akel, O., & Lernmark, Å. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch14 · Cited by 3
Treatment and prevention of type 1 diabetes in the 21st century
Baidal, D. A., Sosenko, J. M., & Skyler, J. S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91707-0.00007-3
Type 1 diabetes: Prevention and screening in focus
Milicic, T. J., Jotić, A., Lukić, L., Macesic, M. V., Gajović, J. S., Stoiljkovic, M. M., Milovancevic, M. M., Rafailović, Đ., Božović, A., Radisavljević, N., et al. (2024) · Medicinska istrazivanja · doi:10.5937/medi57-49676
Advances in type 1 diabetes: Risk factors and prevention
Amutha, A., Ranjani, H., Anjana, R. M., Unnikrishnan, R., & Mohan, V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95469-3.00038-3 · Cited by 1
Müller‐Wieland, D., Miszon, M., Dunstheimer, D., Forst, T. M., Kapellen, T. M., Schnell, O., & Kellerer, M. (2024) · Diabetologie und Stoffwechsel · doi:10.1055/a-2377-7108 · Cited by 1
Impacto del inicio de la monitorización flash de glucosa en pacientes adultos con diabetes tipo 1
Sahagún, R. J. (2024) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/72390
Jönsson, J., & Lernmark, Å. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824465-4.00176-9 · Cited by 1
Zhao, L. P., Papadopoulos, G. K., Skyler, J. S., Parikh, H. M., Kwok, W. W., Lybrand, T. P., Bondinas, G. P., Moustakas, A. K., Wang, R., Pyo, C., et al. (2025) · doi:10.2337/figshare.30559175
Familial assessment and lineage mapping of type 1 diabetes in Ahmedabad India
Saboo, B., Saiyed, M., James, S., & Shah, K. H. (2025) · Discover Public Health · doi:10.1186/s12982-025-01204-2
Hematopoietic Stem Cell Transplant in the Treatment of Autoimmune Endocrine Disease
Schumacher, J., & Carrier, E. (2005) · Humana Press eBooks · doi:10.1385/1-59259-900-1:221
Diabetesprävention bei Kindern
Kordonouri, O. (2011) · Der Diabetologe · doi:10.1007/s11428-011-0727-7
Primär- und Sekundärprävention des Typ-1-Diabetes
Harsunen, M. H., & Warncke, K. (2011) · Der Diabetologe · doi:10.1007/s11428-011-0728-6
Regulation of Immune Responses by Genetically-Engineered Dendritic Cells and Exosomes
Ruffner, M. A. (2010) · D-Scholarship@Pitt (University of Pittsburgh)
Torelogenic nanoparticles for beta cell antigen delivery in type-1 diabetes
Dubreil, C. (2018) · theses.fr (ABES) · doi:10.70675/a1e93e75ze22az4758z9493z0fab68188130
Spotlight on the Pathology of Type 1 Diabetes
Ling, E. M., Lemos, J. R. N., Quesada‐Masachs, E., Hirani, K., & von Herrath, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11985-9.00016-0
Bruggeman, B. S., Jacobsen, L. M., Foster, T. P., & Winter, W. E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-21725-8.00013-5
Diagnosis and ongoing evaluation
Bruggeman, B. S., Jacobsen, L. M., Foster, T. P., & Winter, W. E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-21725-8.00015-9
New Therapeutic Approaches in Diabetes Treatment: Immune Interventions
Allen, L. A., Mahmood, Z. S., & Dayan, C. M. (2026) · Springer eBooks · doi:10.1007/978-3-032-24854-1_28
Grass, L. E., Rodriguez, D. F., Chmiel, R., & Warncke, K. (2026) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-026-02498-5
Miller, J. L., Winter, W. E., & Schatz, D. (2004) · Elsevier eBooks · doi:10.1016/b0-12-475570-4/01435-9
Grotzke, M. P., & Jones, R. E. (2009) · Elsevier eBooks · doi:10.1016/b978-0-323-05885-8.00001-5
Prevention of Islet Graft Rejection and Recipient Tolerization
Akirav, E. M., & Herold, K. C. (2009) · Humana Press eBooks · doi:10.1007/978-1-60761-366-4_13
Metadata
- Authors
- Diabetes Prevention Trial–Type 1 Diabetes Study Group
- Affiliations
- University of Miami (US)
- Corresponding author
- Diabetes Prevention Trial–Type 1 Diabetes Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-05-30
- Volume
- 346
- Issue
- 22
- Pages
- 1685-1691
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W614574849
- Cited by
- 836
- References
- 30
- Citations by year
- 2026: 9 · 2025: 22 · 2024: 24 · 2023: 21 · 2022: 20 · 2021: 32 · 2020: 21 · 2019: 21 · 2018: 22 · 2017: 27 · 2016: 26 · 2015: 34 · 2014: 30 · 2013: 38 · 2012: 42
- FWCI
- 28.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (UC4DK117009)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- type 1 diabetes, insulin therapy, diabetes prevention, relatives of diabetic patients, islet cell antibodies, ultralente insulin, continuous intravenous insulin infusion, glucose tolerance, hypoglycemia, disease progression
- MeSH terms
- Adolescent, Adult, Child, Child, Preschool, Diabetes Mellitus, Type 1, Family, Female, Glucose Tolerance Test, Humans, Hypoglycemia, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Islets of Langerhans, Male, Middle Aged, Risk Factors, Treatment Failure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.